A novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC. Read more
Furmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations. Read more
The third-generation EGFR TKI joins osimertinib in demonstrating a meaningful progression-free survival benefit for consolidation following chemoradiation. Read more
Experts will focus on overcoming barriers in patient advocacy on a global basis and enhancing the patient-physician partnership. Read more
Tuesday morning, nine expert clinicians and researchers in the field will give award lectures in honor of their contributions to the treatment of lung cancer. Read more
Drs. Narjust Florez and Cecilia Pompili will co-chair the session, which will also include tips for improving inclusion in clinical trials, creating a mutually respective work environment, and more. Read more
The association’s most prestigious award was presented to five multidisciplinary teams from around the world during the IASLC Award Ceremony. Read more
From seeing the latest advances in thoracic oncology to connecting with colleagues in the Membership Lounge, you can do it all in the Exhibit Hall. Read more
Edited by lung cancer legends Drs. Fred R. Hirsch and Paul A. Bunn, the book explores the many advances in thoracic oncology treatment throughout the past five decades. Read more
First-line treatment with the novel bispecific antibody ivonescimab in the phase III HARMONi-2 trial improved PFS in patients with advanced NSCLC compared to pembrolizumab. Read more